Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics Corp (MDNAF) is a clinical-stage biopharmaceutical company advancing targeted cytokine therapies for cancer and immune disorders. This news hub provides investors and researchers with verified updates on the company’s therapeutic developments, strategic partnerships, and clinical progress.
Access real-time announcements about MDNAF’s innovative immunotherapy pipeline, including updates on superkine engineering, empowered cytokine platforms, and trial milestones. The repository consolidates essential documents such as earnings reports, regulatory filings, and scientific presentations, offering a comprehensive view of corporate and research activities.
Key content categories include clinical trial advancements, intellectual property updates, executive leadership changes, and collaborative research initiatives. All materials are sourced directly from company communications to ensure accuracy and compliance with disclosure standards.
Bookmark this page for streamlined access to Medicenna’s latest developments in precision immunotherapy. Check regularly for updates on novel therapeutic candidates designed to address unmet needs in oncology through selective cytokine modulation.
Medicenna Therapeutics (OTCQX:MDNAF) reported its Q1 fiscal 2026 results, highlighting significant progress in its immunotherapy pipeline. The company ended Q1 with $20.5 million in cash, providing runway into mid-2026. Operating costs increased to $5.5 million, up from $4.0 million year-over-year, with net loss at $0.06 per share.
Key clinical achievements include promising MDNA11 results, with 30-50% response rates in high-dose patients and complete responses in pancreatic and melanoma cancers. The Phase 1/2 ABILITY-1 trial remains on track for top-line data in H2 2025. The company's IP portfolio expanded to 86 granted patents, strengthening its commercial potential.
R&D expenses increased to $4.2 million from $2.8 million, primarily due to ABILITY-1 Study expansion, while G&A expenses remained stable at $1.3 million.
Medicenna Therapeutics (OTCQX: MDNAF) has strengthened its intellectual property portfolio with five newly granted patents for its IL-2 and IL-4 Superkine platforms. The patents, which expire between 2033 and 2040, cover composition, formulation, combination, use, and therapeutic applications across major global markets.
Key patents include protection for MDNA11 in combination with anti-PD-1 antibodies and a novel formulation of bizaxofusp (MDNA55) for brain cancer treatment. The company's global IP portfolio now includes 86 granted or allowed patents, supporting their clinical pipeline in oncology and autoimmune diseases.
Medicenna Therapeutics (OTCQX: MDNAF) reported its fiscal year 2025 financial results and operational highlights, showcasing significant progress in its clinical programs. The company's lead drug MDNA11 demonstrated compelling anti-tumor activity with response rates of 30-50% in high-dose patients, including three cancer patients remaining tumor-free. Notably, a pancreatic cancer patient has maintained remission for 18 months without additional treatment.
The company reported a net loss of $11.8 million ($0.15 per share) for FY2025, compared to $25.5 million in FY2024. With $24.8 million in cash, Medicenna has runway into mid-2026. Operating costs increased to $20.4 million, primarily due to expanded clinical trial activities. The company plans to complete MDNA11 Phase 1/2 enrollment and report topline data from both monotherapy and combination arms with KEYTRUDA by year-end.
Medicenna Therapeutics has presented promising preclinical data for MDNA113, their novel tumor-targeted immunotherapy candidate, at the 2025 AACR Meeting. MDNA113 is a first-in-class anti-PD-1-IL-2 bifunctional Superkine designed to target IL-13Rα2, which is overexpressed in "immunologically cold" tumors.
The therapy shows potential in treating multiple cancer types, including pancreatic, liver, brain, breast, colon, and prostate cancer, affecting over 2 million patients worldwide. Key findings demonstrate:
- Preferential tumor localization lasting 72+ hours
- Enhanced tolerability through IL-13SK masking
- 100% protection in complete responders against tumor rechallenge
- Improved CD8+ T cell infiltration in tumor models
According to CEO Fahar Merchant, MDNA113's unique approach combines targeted delivery with conditional activation, potentially offering superior results compared to current anti-PD-1-IL-2 bispecifics in development.
Medicenna Therapeutics has presented updated clinical data from its ongoing Phase 1/2 ABILITY-1 study of MDNA11, a long-acting IL-2 super-agonist, at the 2025 AACR Annual Meeting. The study shows promising results both as monotherapy and in combination with KEYTRUDA:
- 10 patients achieved objective response (5 confirmed) in advanced/metastatic cancers resistant to immune checkpoint inhibitors
- 36% objective response rate (ORR) achieved in combination therapy
- 29.4% ORR achieved in monotherapy at ≥60 µg/kg dose
- Highest ORR of 50% observed in MSI-H patients and endometrial cancer patients
The treatment demonstrated an acceptable safety profile with over 90% of treatment-related adverse events being Grade 1-2 and transient. Two patients remain tumor-free and off-treatment after 2-3 years. Phase 2 combination dose expansion is now underway with MDNA11 at 90 µg/kg combined with KEYTRUDA.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto. Dr. Fahar Merchant, President and CEO, will present on Monday, May 5, 2025, at 2:30 p.m. Eastern Time at the Metro Toronto Convention Centre.
The presentation will be accessible via webcast, with a 90-day replay available on Medicenna's Investor Relations website. This prestigious conference connects U.S., Canadian, and international investors with leading Canadian healthcare companies, facilitating corporate updates and one-on-one meetings.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. Dr. Fahar Merchant, President and CEO, will present on April 9, 2025, at 2:00 p.m. Pacific Time at The Venetian Resort.
The presentation will be accessible via webcast through Medicenna's Investor Relations website, with replay available for 90 days. The two-day conference, scheduled for April 8-9, 2025, will feature one-on-one meetings, presentations, fireside chats, panels, and networking opportunities, bringing together select innovative companies and institutional investors.
Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) has announced two upcoming poster presentations at the American Association for Cancer Research Annual Meeting 2025 (AACR 2025) in Chicago, Illinois, from April 25-30, 2025.
The first presentation will provide an update on the Phase 1/2 ABILITY-1 Study of MDNA11, their unique long-acting 'beta-enhanced not-alpha' interleukin-2 (IL-2) super-agonist. This poster will be presented on April 28, 2025, focusing on interim results in patients with advanced solid tumors.
The second presentation, scheduled for April 30, 2025, will showcase pre-clinical data for MDNA113, their novel first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL2 Superkine. Both posters will be made available on Medicenna's website after the conference concludes.
Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) presented new clinical data from the ABILITY-1 study of MDNA11 at the inaugural AACR Immuno-Oncology Conference. The study evaluates MDNA11 alone or combined with Merck's KEYTRUDA® in advanced solid tumors.
Key highlights include MDNA11's ability to significantly expand 'stem-like' CD8+ T cells, which are associated with more persistent anti-tumor activity. In the monotherapy dose expansion cohort, MDNA11 showed a 30% objective response rate in checkpoint-resistant patients. The combination with KEYTRUDA® demonstrated a 78% disease control rate, including one complete response, one partial response, and five stable disease cases.
The Safety Review Committee cleared the 120 µg/kg MDNA11 dose every two weeks in combination with KEYTRUDA®, with no dose-limiting toxicities observed. The company is also exploring dosing every three weeks for improved patient convenience. Additional tumor types will be evaluated, with combination dose expansion expected to begin mid-2025.
Medicenna Therapeutics (OTCQX: MDNAF) reported its Q3 FY2025 financial results and operational updates. Key highlights include a 78% disease control rate in the MDNA11-KEYTRUDA combination arm and a 30% objective response rate in the monotherapy dose expansion cohort. The company maintained a strong financial position with $30 million in cash, expected to fund operations through mid-2026.
The ABILITY-1 trial showed promising results, including one complete response in a 70-year-old patient with advanced anal cancer and one partial response in a colorectal cancer patient. R&D expenses increased to $3.4 million from $3.0 million year-over-year, while G&A expenses slightly decreased to $1.7 million. The company reported a quarterly net loss of $5.2 million ($0.07 per share).
FAQ
What is the current stock price of Medicenna Therapeutics (MDNAF)?
What is the market cap of Medicenna Therapeutics (MDNAF)?
